ATBPF:OTC-Antibe Therapeutics Inc (USD)

COMMON STOCK | Medical Devices | OTC

Last Closing Price

USD 0.50

Change

+0.01 (+1.69)%

Market Cap

USD 0.03B

Volume

0.02M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


ATBPF Stock Forecast & Price:
Based on the Antibe Therapeutics Inc stock forecasts from 0 analysts, the average analyst target price for Antibe Therapeutics Inc is not available over the next 12 months. Antibe Therapeutics Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Antibe Therapeutics Inc is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Antibe Therapeutics Inc’s stock price was USD 0.50. Antibe Therapeutics Inc’s stock price has changed by +9.04% over the past week, +7.16% over the past month and -53.86% over the last year.

About Antibe Therapeutics Inc (ATBPF:OTC)

Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's drugs are designed to prevent the ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-12 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SMMNY Siemens Healthineers AG ADR

-0.21 (-0.78%)

USD59.57B 31.96 14.65
SEMHF Siemens Healthineers AG

N/A

USD58.04B 29.25 14.65
SONVF Sonova Holding AG

N/A

USD22.36B 34.05 23.94
SONVY Sonova Holding AG

-0.19 (-0.26%)

USD21.59B 33.18 23.94
RYLPF Koninklijke Philips N.V

+0.01 (+0.03%)

USD17.92B 44.79 14.17
SNNUF Smith & Nephew plc

-0.82 (-6.23%)

USD11.49B 23.10 11.19
CHEOY CochLear Ltd ADR

-1.59 (-2.00%)

USD10.28B 57.46 22.57
CHEOF Cochlear Limited

N/A

USD9.98B 55.38 22.57
WILLF Demant A/S

N/A

USD8.83B 25.86 2.31
WILYY Demant A/S ADR

+0.55 (+2.92%)

USD8.83B 26.29 2.31

ETFs Containing ATBPF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.41% 80% B- 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.41% 77% C+ 65% D
Trailing 12 Months  
Capital Gain -52.54% 39% F 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -52.54% 38% F 29% F
Trailing 5 Years  
Capital Gain -29.82% 64% D 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -29.82% 62% D- 41% F
Average Annual (5 Year Horizon)  
Capital Gain 11.44% 42% F 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.44% 40% F 49% F
Risk Return Profile  
Volatility (Standard Deviation) 80.80% 48% F 37% F
Risk Adjusted Return 14.16% 42% F 40% F
Market Capitalization 0.03B 51% F 42% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 0.54 91% A- 80% B-
Price / Cash Flow Ratio -1.51 61% D- 70% C-
EV/EBITDA 0.70 34% F 40% F
Management Effectiveness  
Return on Equity -47.15% 34% F 18% F
Return on Invested Capital -47.67% 19% F 13% F
Return on Assets -18.67% 53% F 25% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta -0.05 76% C 84% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector